Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple Negative Breast Cancer: early-phase trial registry
68 of 119 indexed Triple Negative Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #105 of 28,707 conditions by registered trial count.
119 US clinical trials · 68 currently recruiting · #105 of 28,707 conditions by registered trial count
Triple Negative Breast Cancer: 119 US clinical trials tracked, 68 recruiting.
Triple Negative Breast Cancer is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 6 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-cancer
OPEN 68 | RECR 57% | LATE 8 | EARLY 98 | RANK #105 | SPON 6
Volume-matched condition peers
Nearest open-share peer: ACL (57% recruiting · 7 trials)
Triple Negative Breast Cancer lists 68 open slots (57% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple Negative Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple Negative Breast Cancer is recruiting above its size-band peers.
68 of 119 indexed trials (57.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Triple Negative Breast Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 6 of 119 trials (5%). 91 distinct sponsors appear on at least one study for this condition label.
-
Typical Triple Negative Breast Cancer enrolment sits around 77 participants.
Median target enrolment is 77 among the 119 trials that report a genuine target (sentinel values excluded). 67 of those (56.3%) plan for fewer than 100 participants.
-
Triple Negative Breast Cancer research is mostly interventional.
112 interventional and 7 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
119 total, page 2 of 3
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co.
NCT05746897
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04683679
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
NCT06238921
TNBC Gut Microbiota During Neoadjuvant Treatment
Scripps Health
NCT06610097
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05504707
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06245889
Breast Cancer PSMA PET
Ahmad Shariftabrizi
NCT06586047
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06246968
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Alison Stopeck
NCT06220214
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
M.D. Anderson Cancer Center
NCT06318897
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
University of Alabama at Birmingham
NCT04861077
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
H. Lee Moffitt Cancer Center and Research Institute
NCT05809752
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT06435351
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Eileen Connolly
NCT02977468
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
University of Illinois at Chicago
NCT04427293
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Providence Health & Services
NCT06353997
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
Pure Biologics S.A.
NCT06700070
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NSABP Foundation
NCT03281954
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Co.
NCT03401385
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Daiichi Sankyo
NCT07092254
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Gilead Sciences
NCT05382299
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
OBI Pharma
NCT03562637
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Gilead Sciences
NCT05382286
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
NCT06084481
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT04180371
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio
NCT07038369
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Laura M. Spring, MD
NCT04443348
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
University of Kansas Medical Center
NCT03639948
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
NCT03808662
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03891953
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
NCT06449222
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Filipa Lynce, MD
NCT06351332
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
NCT01525966
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co.
NCT04432857
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
NCT02315196
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Priyanka Sharma
NCT02393794
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT02750358
Ribociclib and Bicalutamide in AR+ TNBC
Kari Wisinski
NCT03090165
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Massachusetts General Hospital
NCT04837209
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
NCT02734290
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Mridula George, MD
NCT04445844
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
Massachusetts General Hospital
NCT03945721
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Massachusetts General Hospital
NCT03362060
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
NCT04331067
Comparison of the Breast Tumor Microenvironment
Columbia University
NCT03165487
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
University of Illinois at Chicago
NCT04083963
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 70 |
| Phase 2 | 28 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple Negative Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple Negative Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple Negative Breast Cancer page
119 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 Triple Negative Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Triple Negative Breast Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple Negative Breast Cancer condition card totals 119 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.